{"title":"食管癌的免疫治疗进展如何？","authors":"Rany Aoun","doi":"10.1002/aid2.70006","DOIUrl":null,"url":null,"abstract":"<p>Esophageal cancer (EC) is a challenging malignancy, characterized by late-stage diagnosis and a poor overall prognosis. Recent advancements in immunotherapy have provided new hope for patients, enhancing treatment paradigms and outcomes. This article reviews the latest developments in immunotherapy for esophageal cancer.</p><p>The landscape of EC treatment is evolving rapidly with the advent of immunotherapy. The recent advancements, particularly the use of immune checkpoint inhibitors, have significantly improved patient outcomes and expanded treatment options. However, continued research is needed to optimize these therapies and address remaining challenges.</p><p>This study was financed with internal funds. No competing financial interests exist.</p><p>The author declares no conflicts of interest.</p>","PeriodicalId":7278,"journal":{"name":"Advances in Digestive Medicine","volume":"12 3","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aid2.70006","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy for esophageal cancer: Where are we?\",\"authors\":\"Rany Aoun\",\"doi\":\"10.1002/aid2.70006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Esophageal cancer (EC) is a challenging malignancy, characterized by late-stage diagnosis and a poor overall prognosis. Recent advancements in immunotherapy have provided new hope for patients, enhancing treatment paradigms and outcomes. This article reviews the latest developments in immunotherapy for esophageal cancer.</p><p>The landscape of EC treatment is evolving rapidly with the advent of immunotherapy. The recent advancements, particularly the use of immune checkpoint inhibitors, have significantly improved patient outcomes and expanded treatment options. However, continued research is needed to optimize these therapies and address remaining challenges.</p><p>This study was financed with internal funds. No competing financial interests exist.</p><p>The author declares no conflicts of interest.</p>\",\"PeriodicalId\":7278,\"journal\":{\"name\":\"Advances in Digestive Medicine\",\"volume\":\"12 3\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aid2.70006\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Digestive Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/aid2.70006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Digestive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/aid2.70006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Immunotherapy for esophageal cancer: Where are we?
Esophageal cancer (EC) is a challenging malignancy, characterized by late-stage diagnosis and a poor overall prognosis. Recent advancements in immunotherapy have provided new hope for patients, enhancing treatment paradigms and outcomes. This article reviews the latest developments in immunotherapy for esophageal cancer.
The landscape of EC treatment is evolving rapidly with the advent of immunotherapy. The recent advancements, particularly the use of immune checkpoint inhibitors, have significantly improved patient outcomes and expanded treatment options. However, continued research is needed to optimize these therapies and address remaining challenges.
This study was financed with internal funds. No competing financial interests exist.
期刊介绍：
Advances in Digestive Medicine is the official peer-reviewed journal of GEST, DEST and TASL. Missions of AIDM are to enhance the quality of patient care, to promote researches in gastroenterology, endoscopy and hepatology related fields, and to develop platforms for digestive science. Specific areas of interest are included, but not limited to: • Acid-related disease • Small intestinal disease • Digestive cancer • Diagnostic & therapeutic endoscopy • Enteral nutrition • Innovation in endoscopic technology • Functional GI • Hepatitis • GI images • Liver cirrhosis • Gut hormone • NASH • Helicobacter pylori • Cancer screening • IBD • Laparoscopic surgery • Infectious disease of digestive tract • Genetics and metabolic disorder • Microbiota • Regenerative medicine • Pancreaticobiliary disease • Guideline & consensus.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
